- Home
- VYNE vs LRE Comparison
VYNE vs LRE Comparison
Compare VYNE & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VYNE | LRE |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0M | 17.2M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | VYNE | LRE |
|---|---|---|
| Price | $0.60 | $1.36 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 323.6K | 17.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $1.00 |
| 52 Week High | $2.05 | $2.86 |
Technical Indicators
Market Signals| Indicator | VYNE | LRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 50.52 |
| Support Level | $0.55 | $1.34 |
| Resistance Level | $0.60 | $1.57 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 56.07 | 41.18 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.